

RESEARCH ARTICLE

Open Access

Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples

Karin Elberse^{1*}, Suzan van Mens², Amelieke J Creemers^{4,5}, Sabine CA Meijvis³, Bart Vlaminckx², Marien I de Jonge^{4,5}, Jacques F Meis^{6,7}, Cornelis Blauwendraat¹, Ingrid van de Pol¹ and Leo M Schouls¹

Abstract

Background: Treatment of community acquired pneumonia (CAP) patients with antibiotics before laboratory-confirmed diagnosis leads to loss of knowledge on the causative bacterial pathogen. Therefore, an increasing number of pneumococcal infections is identified using non-culture based techniques. However, methods for serotyping directly on the clinical specimen remain scarce. Here we present three approaches for detection and serotyping of pneumococci using samples from patients with CAP.

Methods: The first approach is quantitative PCR (qPCR) analysis on blood samples (n = 211) followed by capsular sequence typing (CST) to identify the serotype. The second approach, a urinary antigen assay (n = 223), designated as inhibition multiplex immunoassay (IMIA), is based on Luminex technology targeting 14 serotypes. The third approach is a multiplex immunoassay (MIA) (n = 171) also based on Luminex technology which detects serologic antibody responses against 14 serotypes. The three alternative assays were performed on samples obtained from 309 adult hospitalized CAP patients in 2007–2010 and the results were compared with those obtained from conventional laboratory methods to detect pneumococcal CAP, i.e. blood cultures, sputum cultures and BinaxNOW[®] urinary antigen tests.

Results: Using qPCR, MIA and IMIA, we were able to detect the pneumococcus in samples of 56% more patients compared to conventional methods. Furthermore, we were able to assign a serotype to the infecting pneumococcus from samples of 25% of all CAP patients, using any of the three serotyping methods (CST, IMIA and MIA).

Conclusion: This study indicates the usefulness of additional molecular methods to conventional laboratory methods for the detection of pneumococcal pneumonia. Direct detection and subsequent serotyping on clinical samples will improve the accuracy of pneumococcal surveillance to monitor vaccine effectiveness.

Keywords: *Streptococcus pneumoniae*, Pneumococcus, Community acquired pneumonia, Detection, Serotype, Blood, Urine

Background

Streptococcus pneumoniae is a major human pathogen causing considerable morbidity and mortality throughout the world. It is considered the main cause of community acquired pneumonia (CAP) [1,2], although there is little consensus in the literature on the prevalence of pneumococci in CAP, it ranges from 10 to 48% in hospitalized

patients [1]. Differences are observed between countries and health care settings, but also differences in methods used to identify the causative agent contribute to the diverse numbers of prevalence [3,4]. The lack of sensitive methods to identify the pathogen adds to the problem [5-10]. Furthermore, patients are often treated with antibiotics before the collection of specimens for laboratory diagnosis, making the identification of the causative agent more problematic.

Standard microbiology assays to detect the pneumococcus as the causative agent of CAP are culture from sputum and/or blood, sputum gram stain and the BinaxNow

* Correspondence: Karin.Elberse@RIVM.nl

¹Centre for Infectious Disease Control Netherlands, National Institute for Public Health and the Environment (RIVM), Laboratory for Infectious Diseases and Perinatal Screening, Antonie van Leeuwenhoeklaan 9, P.O.Box 1, 3720 BA Bilthoven, The Netherlands

Full list of author information is available at the end of the article

S. pneumoniae test. The BinaxNow test is a rapid antigen test on urine or cerebrospinal fluid, which detects pneumococcal cell wall polysaccharides (CWPS). Specificity and sensitivity are high in adults for the diagnosis of pneumococcal CAP compared with conventional methods [6,11,12]. In children, specificity is much lower due to high carriage rates [5,13]. Developed assays for detection of pneumococcal DNA in blood samples include PCR and quantitative PCR (qPCR) [14-16]. Recently, a few studies described the use of PCR to identify the serotype directly from pneumococcal DNA present in blood [17-19]. These PCRs contain a myriad of primers and/or probes, using single- or multiplex reactions, making the method complex.

Currently, over 90 pneumococcal serotypes have been described and roughly a quarter of these serotypes are responsible for the majority of cases of invasive pneumococcal disease (IPD) [20-24]. Serotyping of pneumococci is essential in monitoring the effects of nationwide vaccine introduction. The classical technique for serotyping is the Quellung reaction, based on reactivity of the capsular polysaccharides with specific antisera [7,25]. To identify a pneumococcal serotype using the Quellung reaction, a cultured isolate must be present. The Quellung reaction is time-consuming and expensive because a whole collection of antisera is needed for the identification of all serotypes. Many alternative serotyping methods have been developed [17-19,26]. One of these is the Capsular Sequence Typing (CST) [27,28], a method based on the sequence obtained from a single PCR product of the capsular gene *wzh*.

Measurement of serotype-specific antibodies has been time-consuming due to the lack of multiplexing ability of the Enzyme-linked immuno sorbent assay (ELISA). With the introduction of the Luminex platform, simultaneous measurement of IgG concentrations directed against a large number of different capsular polysaccharides in a single assay became possible. This method was first described by Pickering et al. for pneumococci [29] and later adjusted and optimized by others [30,31]. In a sandwich or inhibition version of the first described pneumococcal Luminex assay, also detection of pneumococcal polysaccharides in urine samples appeared to be possible [10,32,33].

In this study, we describe three methods to assess the pneumococcal serotype directly from urine and blood. We developed an assay to conduct the serotyping by CST directly on pneumococcal DNA isolated from blood samples by a rapid extraction method. Furthermore, we describe an inhibition assay approach to detect pneumococcal capsular polysaccharides of 14 different serotypes in urine. The serotypes covered by this assay represent the serotypes in the 13-valent pneumococcal vaccine and serotype 8 which is frequently found in IPD patients. The

third assay is previously described and detects the causative pneumococcus by a positive antibody response [9]. The methods are used to detect and serotype pneumococci in CAP patients and the results from these assays are compared with conventional microbiology assays.

Methods

Clinical samples

Blood and urine samples were obtained from hospitalized CAP patients aged 18 to 100 years, who participated in a trial assessing the effect of dexamethasone use in CAP. This study was carried out in the St. Antonius Hospital, Nieuwegein, The Netherlands and is described in detail elsewhere [34]. Mean age of the enrolled patients was 63 years old and approximately 27% of the patients started antibiotic treatment before enrolment. Samples were collected from November 2007 to September 2010 and conventional laboratory methods to identify the causative agent of CAP were performed. Additionally, ethylenediamine-tetra-acetic acid (EDTA) blood samples for molecular testing were obtained on the day of admission and sent to the National Institute for Public Health and the Environment (RIVM) within 1 day after the blood was drawn. Urine samples for IMIA antigen testing were collected on the day of admission, sent to the RIVM and stored at -20°C until use. Serum samples for the detection of antibody responses by MIA were obtained on the day of admission and at day 30 after admission and stored at -80°C . Eligible patients provided written informed consent and the study was approved by the institutional Medical Ethics Committee of the St. Antonius Hospital. This study was registered with ClinicalTrials.gov, number NCT00471640. For comparison of the CST, serum samples and blood culture isolates were collected from adults with pneumococcal bacteremia hospitalized in a different institution between December 2008 and June 2013.

Conventional laboratory methods

Diagnostic tests were performed on sputum, blood and urine samples at the day of admission to identify the causative agent of CAP as previously described [34]. Briefly, sputum samples were Gram stained and cultured and at least two blood cultures were performed (BacT/Alert; bioMérieux, Marcy l'Etoile, France). Urine samples were used for detection of *S. pneumoniae* antigen (BinaxNOW *S. pneumoniae*, Inverness Medical). The serotypes of the pneumococcal isolates used for comparison of the CST were determined by multiplex PCR analysis of the *cps* locus as described by Pai et al. [26] or by Quellung reaction [25].

Molecular blood tests

Sample preparation

EDTA blood sample tubes were centrifuged for 10 minutes at $400\times g$. A milliliter of plasma was transferred to

a clean tube and was centrifuged for 10 minutes at 14000xg. After transferring the plasma, the pellet was centrifuged again for one minute at 14000xg and residual plasma was discarded. From the pellet the pneumococcal DNA was extracted using the Extract-N-Amp Plant PCR Kit (Sigma-Aldrich, St. Louis, MO, USA). In detail, 25 µl of extraction buffer was added to the pellet and incubated at 95°C for 10 minutes. Thereafter, 25 µl of dilution buffer was added and the material was ready for use in the qPCR. For use in the CST, the samples were purified using a Sephadex column (G-50, GE Healthcare, Chalfont St. Giles, UK), according to manufacturer's protocol.

From 200 µl serum samples used for comparison of the CST, total DNA was extracted using the MagNA Pure 96 Pathogen Universal 200 Kit (Roche Diagnostics, Indianapolis, IN, USA) and eluted in 100 µl elution buffer.

Detection qPCR

The quantitative PCR was based on two target genes, *ply* and *lytA*, as described before [8,35]. Sequences of the primers and probes are provided in Table 1. An internal control was added to detect inhibitors of amplification and contained a primer site for the *lytA* forward primer and a primer site for the *ply* reverse primer. To amplify the two gene segments, 10 µl PCR mixtures containing QuantiTect Multiplex PCR NoROX Kit, (Qiagen, Hilden, Germany), 0.6 µM of each primer, 0.3 µM of each probe, 1000 copies of internal control and 2 µl of the extracted DNA were used. The PCR reaction was as follows: 2 min 50°C, 15 min 95°C and 40 cycles of 15 sec 95°C and 1 min 65°C in a LightCycler 480 (Roche, Mannheim, Germany). The standard curve consisted of PCR products of *ply* and *lytA* gene segments which were purified using Qiaquick PCR Purification Kit (Qiagen) and quantified using a spectrophotometer (Nanodrop ND-1000, Thermo Scientific, Wilmington, DE, USA). The PCR was considered positive for pneumococci if at least one of the duplicate samples yielded a fluorescent signal for *lytA*.

For comparison, the qPCR was performed by amplification of a segment of the *lytA* gene only. The primer and probe sequences were different from those applied in the sample set of the general study (Table 1). The 25 µl PCR mix contained 1x TaqMan® Universal PCR Master Mix, No AmpErase® UNG, 0.2 µM of each primer, 0.2 µM probe and 8 µl of the extracted DNA. Thermal cycling was performed in a 7500 Fast Dx qPCR Instrument (Applied Biosystems® Foster City, CA, USA) with the following cycling conditions: 2 min 50°C, 10 min 95°C and 50 cycles of 15 sec 95°C and 1 min 60°C. The standard curve consisted of a 10-fold dilution series of genomic pneumococcal DNA extracted by the Qiagen Genomic-tip 20/G Kit (Qiagen) and quantified by a spectrophotometer (Nanodrop ND-1000).

Table 1 Oligonucleotide primers, probes and internal control sequences

Assay	Name	Sequence	
qPCR	Sp- <i>ply</i> -531 F ¹	AGCGATAGCTTTCTCCAAGTGG	
	Sp- <i>ply</i> -583R ¹	CTTAGCCAAACAATCGTTTACCG	
	Sp- <i>lytA</i> -306 F ¹	ACGCAATCTAGCAGATGAAGC	
	Sp- <i>lytA</i> -386R ¹	TGTTTGGTTGGTTATTCGTGC	
	Sp- <i>lytA</i> -CDCF ²	ACGCAATCTAGCAGATGAAGCA	
	Sp- <i>lytA</i> -CDCR ²	TCGTGCGTTTTAATTCACGT	
	Sp- <i>ply</i> -556probe ¹	FAM-ACCCAGCAATCAAGTG TTCGCG-BHQ1	
	Sp- <i>lytA</i> 330-probe ¹	Cy5-TTGGCCGAAAACGCTTGA TACAGGG-BHQ3	
	Sp- <i>lytA</i> -CDCprobe ²	FAM-GCCGAAAACGCTTGATA CAGGGAG-BHQ1	
	Sp- <i>lytA</i> -probe ²	FAM-TTGGCCGAAAACGCTTGA TACAGGG-TAMRA	
	Sp-Spike-qPCR ³	ACGCAATCTAGCAGATGAAGC TATCATGGCGACGTGTTTCATG CAGATATATCGGTAACGATTT GTTGGCTAAG	
	Sp-spike-probe ³	HEX-CATGGCGACGTGTTTCAT GCAGATA-BHQ1	
	Clinical CST	CST_01-M13F	GTA AACACGACGCCAGCATTG GCATATCGTTTTTG
		CST_03-M13F	GTA AACACGACGCCAGCATTG GCACATCGTCTTTG
M13wzh1553F		GTA AACACGACGCCAGACCAT TGCTCTACCTCTCAC	
M13wzh1553Fst3		GTA AACACGACGCCAGATGAT TGCTCTACTTCGCAT	
M13wzh1747R		CAGGAAACAGCTATGACATCA AGGCATAACGACTATCA	
CST_01-M13R		CAGGAAACAGCTATGACCTGA GCTCTTTTTTCATGA	
CST_04-M13R		CAGGAAACAGCTATGACCCGA GCTCTTTTTTCATGA	
M13F		GTA AACACGACGCCAG	
M13R		CAGGAAACAGCTATGAC	

¹used in the general study [8,35].

²used in the comparison sample set [40].

³DNA sequence used for internal control of the qPCR.

Capsular sequence typing (CST)

In CST a partial segment of the capsular gene *wzh* of the pneumococcus is amplified and subsequently sequenced [27]. Based on this sequence the capsular genotype is assigned, designating the serotype. In this study, the CST protocol was adapted to be performed directly on blood plasma samples and serum. To enhance sensitivity, the gene segment used in CST was amplified and sequenced in two overlapping segments which we subsequently assembled to create a single sequence. The primers were designed with 5'-M13-tails to facilitate DNA sequencing with a single M13 primer set (Table 1). To amplify the

two gene segments 25 µl PCR mixtures containing Hotstar-taq mix (Qiagen), 10 µM of each primer and 5 µl Sephadex purified DNA template were used. The PCR reaction was performed as follows: 15 min 95°C, 10 cycles of 20 sec 95°C, 30 sec 61–51°C and 30 sec 72°C followed by 35 cycles of 20 sec 95°C and 1 min 72°C, followed by 7 min 72°C. PCR products were purified using ExoSAP-IT (GE Healthcare Life Sciences) according to the manufacturer's instructions. One µl aliquots of the purified PCR products were used in sequence reactions with M13 forward and reverse primers using Big Dye Terminator technology (Applied Biosystems) on an AB 3730 genetic analyser. Data analysis for CST was performed using Bionumerics version 7.0 (Applied Maths, Sint-Martens-Latem, Belgium). All sequences of the CST were assembled, edited, trimmed and assigned a capsular type. A capsular type is a composite assignment; the first part of the assignment is based on the phenotype assessed by conventional serotyping and the second part of the assignment is the consecutive number of the capsular type belonging to the same serotype. As an example, CT09V-01 designated the first variant in *wzh* sequence of an isolate serotyped as 9V. The CST database is publicly available through www.rivm.nl/mpf/spn/cst.

Inhibition multiplex immunoassay (IMIA) for polysaccharide detection in urine

Urine samples were thawed and 2 ml urine was added to 2 ml absolute ethanol and incubated at 4°C overnight. Samples were centrifuged for 15 min at 3200xg, supernatant was discarded and the pellet was resolved in 100 µl PBS (pH 7.2) and heated for 10 min at 95°C. After the samples were centrifuged for 15 min at 2000xg the supernatant was stored at -20°C until use in the IMIA.

The coupling of the polysaccharides to carboxylated microspheres (Bio-Rad Laboratories, Hercules, CA, USA) was performed as previously described [30,33]. Briefly, purified capsular polysaccharides were conjugated to Poly-L-Lysine. The conjugates were coupled to carboxylated microspheres. All capsular polysaccharides were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) except for polysaccharide 6A which was kindly provided by Pfizer Inc. (New York, NY, USA). Type and factor rabbit sera were obtained from Statens Serum Institut in Denmark and were purified using Melon Gel IgG Purification Kit (Thermo Fisher Scientific Inc., Rockford, IL USA) according to manufacturer's protocol. The antisera against 14 serotypes were pooled and incubated overnight at 4°C in adsorbent buffer containing 15 µg/ml CWPS Multi and 5% antibody depleted human serum (ADHS, Valley Biomedical, Winchester, VA) in PBS (pH 7.2). The mixture contained antisera in the following dilutions: serotype 9V, 1:300; serotypes 6A, 6B, 8, 18C, 23F, 1:1,000; serotypes 3, 4, 1:1,600; serotype 7E, 1:2,000; serotype 19A, 1:5,000; serotype 19F,

1:8,000; serotype 1, 1:10,000; serotype 14, 1:21,600 and serotype 5, 1:150,000.

An aliquot of 25 µl of urine samples was incubated in duplicate for 1 h at room temperature with 25 µl of the pooled antiserum on a plate shaker. Subsequently, per well 4000 beads of each serotype specific microsphere set were added and incubated for 1 h at room temperature on a plate shaker. After the microspheres were washed using PBS-Tween, the beads were incubated for 20 min at room temperature with 100 µl of a 1/200 dilution of R-phycoerythrin-conjugated anti-rabbit IgG (Southern Biotechnology, Birmingham, AL, U.S.A.). After another wash of the microspheres, 125 µl PBS-Tween was added and microspheres were analysed using the Bio-Plex 100 (Bio-Rad, Hertfordshire, United Kingdom). Detection of polysaccharide in urine samples was considered positive using a 30% positivity cut-off value from the mean median fluorescent intensity (MFI) of duplicate pooled samples without competitive inhibition. The intra-run reproducibility was calculated as the coefficient of variation (CV) of replicates and a CV of 10% was considered to be acceptable. Polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7E, 8, 9V, 14, 18C, 19A, 19F and 23F were pooled and prepared in 10-fold dilutions from 1000 ng/ml to 0.01 ng/ml in PBS and were used as reference range in the assay.

Multiplex Immunoassay (MIA) for assessment of longitudinal antibody concentrations

In two consecutive serum samples, an early (day 0–3) and late (day 11–100) sample, pneumococcal antibody concentrations were measured against 14 different serotypes (1, 3, 4, 8, 9N, 12E, 14, 19E, 23E, 6B, 7E, 18C, 19A, and 9V) using Luminex XMAP technology. Antibody concentrations were calculated by interpolation from a 5-parameter logistic standard curve [36,37], plotting the MFI against the polysaccharide concentration (Luminex software). A positive antibody response was defined as a serotype-specific twofold increase in antibody concentrations between the two samples. This method is described in more detail elsewhere [9].

Statistical analysis

Statistical tests were performed using Graphpad Quickcalc software. Agreement between two tests was assessed by Cohen's kappa (κ) statistic, with values indicating poor (0.00–0.20), fair (0.21 to 0.40), moderate (0.41–0.60), good (0.61–0.80) and excellent agreement (0.81–1.00).

Results

Optimization and implementation of the qPCR, CST and IMIA methods

Quantitative detection using qPCR was based on two target genes, *ply* and *lytA*. Overall, the *ply* target yielded amplification signals in more samples as compared to

the *lytA* target indicating possible false positivity. Therefore, a sample was considered positive for pneumococci if at least one of the duplicate samples yielded a fluorescent signal for *lytA*. Based on serial dilutions of quantified PCR products, the detection limit was estimated to be 1.6 gene copies per microliter extracted DNA per PCR. The minimal bacterial load, determined using colony forming units (CFU) dilution series, that could be detected in the qPCR was 75 CFU per milliliter blood. Specificity of the assay was high as genomic DNA of closely related Streptococci, including *S. oralis*, *S. gordonii*, *S. parasanguinis*, *S. sanguinis* and *S. mitis* and *S. mutans* did not yield PCR products. To determine which serotypes can be detected using the primers amplifying the two overlapping segments in CST, lysates of pneumococcal isolates of the 45 serotypes most prevalent among IPD patients in The Netherlands were tested. Only the isolates with serotypes 10A, 22A, 23A, 24F, 25, 38 and 35B yielded non-specific or no PCR products in 1 of the two PCRs. The minimum amount of DNA required to perform typing by CST was around 11 gene copies per PCR. Once the assay was optimized, a comparison set of serum samples from 19 pneumococcal CAP patients were analysed by CST. In the serum samples with a bacterial load of >1800 gene copies per ml serum, a serotype could be identified by CST (Table 2). The serotypes identified were serotype 3 (5x), 19A (2x), 7F (2x), 4 (2x) and serotype 8 (1x) and there was full concordance between CST on serum and Quellung reaction and/or multiplex PCR on blood culture isolates.

Specificity of the IMIA was assessed with a mixture of polysaccharide coated microspheres and pooled antisera, spiked with polysaccharides from a single serotype for inhibition. This method enabled the identification of all serotypes with negligible cross reactivity. The minimal required concentration of polysaccharides for the assay was assessed using spiked polysaccharides in urine and was between 1 and 10 ng/ml urine.

Comparison of qPCR, IMIA and MIA with the conventional methods

A total of 309 patients were enrolled in this study and in these patients the causative agent of CAP was investigated using conventional microbiological methods. For 211 (68%) patients, blood was available for detection of pneumococci by qPCR and CST was performed if the samples were positive in the qPCR. The IMIA was performed on urine of 223 (72%) of the enrolled CAP patients. The serologic antibody response was assessed on samples of 171 (55%) patients. In 64 (21%) patients the pneumococcus was identified as causative agent of CAP by at least one conventional microbiological method: blood culture (28/301, 9%), sputum culture (15/294, 5%) and/or BinaxNOW urinary antigen test (52/307, 17%)

Table 2 Serotypes and bacterial load assessed in the comparison set (n = 19 samples of bacteremic patients)

Copies/ml serum	Serotype by Quellung/multiplex PCR	Capsular type by CST on serum
22319	4	04-01
16865	3	03-01
15933	19A	19A-01*
10243	19A	19A-01
9803	3	03-03
8260	3	03-01
5954	7 F	07 F-01
5767	8	08-01
5533	7 F	07 F-01
1961	4	04-0*
1852	3	03-0*
1804	3	03-03
670	NT	no seq.
656	8	no seq.
155	5	no seq.
123	1	no seq.
122	8	no seq.
101	9 V	no seq.
92	7 F	no seq.

*Sequence <506 bp.

No seq., no sequence obtained or not possible to determine the serotype.

(Table 3). In total, 8% (16/211) of patients were positive for pneumococcal infection using the qPCR, 17% (39/223) of patients using the IMIA and 22% (37/171) using the MIA for serologic antibody response. The different assays respectively obtained sensitivity of 29% (13 samples were qPCR positive of the 45 available samples for qPCR of patients that were positive by any of the conventional methods, Table 3), 43% (IMIA; 20/47) and 40% (MIA; 19/48) of the pneumococcal pneumonia patients identified by conventional methods.

An additional 36 patients (56% increase, 100 patients in total), who were not recognized as pneumococcal CAP patients using the conventional methods, had a positive result in any of the three alternative methods. Four of these patients had a positive result in ≥ 2 of the alternative test methods. For two patients, samples had a positive result by CST and IMIA, and for two patients, samples had a positive result by MIA and IMIA (data not shown). The MIA and IMIA resulted in similar percentages of positive samples when conventional tests were negative (MIA 15%, 18/123; IMIA 11%, 19/176). The qPCR performed on blood samples detected lower number of additional positives (2%, 3/166) (Table 3).

Comparing the results from the assays that make use of the same clinical materials, in 20 patients for whom

Table 3 Contribution of the alternative methods to the diagnosis of pneumococcal CAP

	Total	All conventional tests			Blood culture			BinaxNow			Sputum culture		
		Pos N (%)	Neg N (%)	Nd N	Pos N (%)	Neg N (%)	Nd N	Pos N (%)	Neg N (%)	Nd N	Pos N (%)	Neg N (%)	Nd N
Total	309	64	245		28	273	8	52	255	2	15	279	15
qPCR													
Pos	16	13 (29)	3 (02)		9 (45)	4 (2)	3	10 (29)	6 (3)	0	4 (33)	9 (5)	3
Neg	195	32 (71)	163 (98)		11 (55)	180 (98)	4	24 (71)	169 (97)	2	8 (67)	176 (95)	11
Nd	98	19	79		8	89	1	18	80	0	3	94	1
IMIA													
Pos	39	20 (43)	19 (11)		11 (55)	27 (14)	1	16 (41)	23 (13)	0	3 (38)	32 (16)	4
Neg	184	27 (57)	157 (89)		9 (45)	171 (86)	4	23 (59)	161 (86)	0	5 (62)	172 (84)	0
Nd	86	17	69		8	75	3	13	71	2	7	75	4
MIA													
Pos	37	19 (40)	18 (15)		9 (43)	26 (10)	2	13 (36)	23 (9)	1	6 (40)	23 (9)	8
Neg	134	29 (60)	105 (85)		12 (57)	230 (90)	4	23 (64)	222 (91)	1	9 (60)	232 (91)	5
Nd	138	16	125		7	17	2	16	10	0	0	24	2

Pos: positive, Neg: negative, Nd: not done/not available.

blood culture was positive and material for qPCR was available, 45% (9/20) yielded a positive qPCR (Table 3). In contrast, in blood culture negatives, 2% (4/184) of the samples were positive by qPCR. Antibody responses measured by MIA provided a similar number of positive results compared to blood culture. 43% (9/21) Of the patients that were found positive for pneumococci using blood culture, showed an antibody response using MIA. Of BinaxNOW positive patients, 41% (16/39) had a positive result in IMIA as well. An additional 13% (23/184) of BinaxNOW negative patients were tested positive by IMIA. Notably, in a patient the pneumococcal infection was provisionally diagnosed by sputum culture (n = 15), the alternative tests yielded the lowest number of positive tests. The IMIA yielded the largest number of positives if sputum cultures were negative (16% (32/204)). Specificity of the assays were 84% (32/204; IMIA vs. Sputum culture) and up to 98% (4/184; qPCR vs. blood culture). The cohens κ of agreement between assays ranged from 0.083 (poor; Sputum culture vs. IMIA) and 0.507 (moderate; Blood culture vs. qPCR) and was on average 0.288 (fair agreement).

Serotypes deduced by alternative methods

The alternative methods enabled the identification of the serotypes in samples from 25% of all CAP patients (68 of 278 samples assessed using any of the alternative methods). In comparison, Quellung could have been performed on the infecting pneumococcus of 14% of patients (43 of 308 patients were found positive using blood or sputum culture). There was good concordance between the results obtained in the three methods. Serotypes 3 and 8 were the most frequently identified pneumococcal serotypes, each found in 15 patients (22%) (Table 4). Serotype 1, 9 V and 7 F were detected in samples from 7 (10%), 6 (9%) and 3 (4%) patients, respectively. In samples from 16 of the 68 patients (24%), two or more methods yielded identical serotypes.

Once, the identical serotype was detected in all three different methods. In three cases, different methods yielded conflicting results. However, in these cases ambiguous IMIA results were included with weak signals for multiple serotypes.

Discussion

In this study, samples from patients with CAP were used to evaluate the sensitivity of detection of *S. pneumoniae* with three different methods and to assess the added value for serotyping by non-culture methods. The advantage of the methods described in this study is that they can be used after antibiotic treatment and are time-saving, as culturing is not required. To the best of our knowledge, this is the first study that compares multiple assays used for detection and serotyping of pneumococci directly from clinical samples without the use of culture. The results of the three alternative methods revealed considerable overlap with the results of the conventional methods. Using the alternative methods, we were able to detect the pneumococcus in samples from 56% more patients compared to conventional methods, providing there were no false positive samples. Furthermore, of all patients with pneumonia, a pneumococcal serotype was determined in 25% using PCR/CST, IMIA and MIA as compared to 14% in which an isolate was available for serotyping using conventional methods

In general, the sensitivities of the individual tests described in this study are in line with similar assays developed by others. In our study, a number of samples were not available for each test. If only the patients for whom all tests were performed were included, sensitivity and specificity were higher compared to the numbers provided here. However, numbers were small and therefore we presented the data from the incomplete sampling.

In our study we enrolled patients with a pneumococcal CAP and non-pneumococcal CAP. The non-pneumococcal

Table 4 Distribution of serotypes in this study detected by CST, MIA and IMIA

Serotypes	Frequency ¹	Percent	CST (number tested: n = 16)	MIA (number tested: n = 171)	IMIA (number tested: n = 223)
3	15	22	3	6	11
8	15	22	1	10	8
1	7	10	4	2	6
9V	6	9	1	2	4
7F	3	4	0	4	0
19A	2	3	0	2	1
4	2	3	1	3	0
6B	2	3	1	2	1
12F	1	1	0	1	NA
14	1	1	0	3	0
18C	1	1	0	1	0
23F	1	1	0	0	1
6A	1	1	0	NA	1
9N	1	1	0	1	NA
Ambiguous ²	10	15			6
Total	68	100	11	37	39

¹Number of the patients infected with a given serotype detected by any of the methods.

²No serotype could be determined because of cross reactivity with multiple serotypes in the IMIA or ambiguous results between methods. NA. not applicable, serotype could not be assessed using the method.

CAP patients account for the controls and are used to calculate specificity. However, it would have been valuable to include non-pneumonia patients for specificity calculations. Conventional tests (blood cultures, sputum cultures and BinaxNOW urinary antigen test) lack sensitivity and are therefore a far from ideal golden standard for specificity calculations. Positive results in the investigated assays for patients with negative results in the conventional tests should not be regarded as false-positive.

In a study by Abdeldaim et al., in CAP patients, the percentages (9%) of *lytA* PCR positive samples was comparable, but sensitivity of the *lytA* PCR compared to blood culture was slightly higher [38]. Cremers et al. showed a considerable higher number of qPCR positives (68%) in adults with blood-culture proven pneumococcal CAP [16]. In a study by Marchese et al., the sensitivity of the qPCR compared to blood culture was considerably higher, but this study included only pediatric patients [17]. In pediatric patients the blood culture positivity rate is considerably lower, which may be explained by lower bacterial load in children and small sample volumes of pediatric patients [39]. Also, differences in the amount of template DNA and number of PCR cycles could account for the differences in sensitivity between these studies. Also, primers used in these studies differed from our study. These factors may influence the sensitivity. The detection limit of the qPCR described here is comparable to the proposed CDC method, both <10 copies per PCR reaction [40]. In the

comparison set as well as the general study, above a specific pneumococcal density threshold CST on clinical specimens from CAP patients was successful and accurate, despite differences in study region, cohort characteristics, clinical specimen, extraction method and qPCR conditions. The qPCR used in this study is based on the previously published qPCRs, described by McAvin et al. for *lytA* [8] and Greiner et al. for *ply* [35]. Other detection qPCR for pneumococci have been proposed, targeting these or other genes [40–42]. The *lytA* gene has been showed to be highly specific [40], whereas the *ply* gene is also carried by other flora normally present in the respiratory tract, such as *S. mitis* and *S. oralis*, and therefore may produce false positives in detection of pneumococci [40,42,43]. The *ply* target was amplified in more samples compared to the *lytA* target, indicating the non-specificity of the *ply* gene and indicating the correct choice of *lytA* as the primary target for the detection of pneumococci. The same was described in the study of Palmu et al. [42]. In our study, 69% of the blood samples with positive result in the qPCR could be assigned a serotype using CST. In the study by Marchese et al., molecular serotyping directly on blood was successful in 36 of the 46 (80%) samples from pediatric patients infected by pneumococci confirmed by culture and/or molecular test (real-time PCR amplification of both *lytA* and *cpsA* genes) [17]. In another study, in 73 of the 80 qPCR positive blood samples a serotype could be detected from patients of 0–16 years of age using specific PCRs to detect 21 different serotypes [18]. The

CST has proven to be a valuable method to assess the serotype of an isolate in over 3000 isolates [27,28] (www.rivm.nl/mpf/spn/cst). Also, the method is quick and easy to perform. Because this method is based on a single gene in the capsular gene locus, some serotypes cannot be distinguished, eg. serotypes 18B and 18C. In general, one of the serotypes with corresponding sequence is not common in invasive pneumococcal disease, such as serotype 18B, but we are currently improving this assay to enable differentiation between those serotypes. Because the PCR target of the CST was divided in 2 segments to improve sensitivity, some serotypes could no longer be detected by this technique. However, the undetectable serotypes (serotypes 10A, 22A, 23A, 24F 25, 38, 35B) accounted for approximately 4% of IPD after vaccine introduction (data annual report of Dutch pneumococcal surveillance). Therefore, the increase in sensitivity caused by the amendment of the original assay outweighed the loss of the detection of these serotypes for the Dutch situation. However, in other parts of the world these serotypes may have increased after vaccine implementation [44].

The inhibition multiplex immunoassay (IMIA) described here detects the 13 serotypes included in PCV13 and serotype 8, because of the high incidence of invasive disease caused by this serotype. A similar assay was described by Findlow et al. with comparable sensitivity and specificity [33]. Main differences were the use of CPS multi as a sorbent and the use of rabbit antisera instead of a reference serum with a limited supply. In a different study using the Luminex platform, a serotype detection system was developed in an antigen capture approach. This assay uses monoclonal antibodies coupled to the microspheres and polysaccharide is detected in urine with the use of polyclonal anti-polysaccharide antibodies [10]. The authors showed a high specificity, which was supposed to be a benefit from the use of monoclonal antibodies. In an immune-inhibition approach like our method, commercially available antiserum is used. The use of commercially available antisera provides the possibility to expand the assay easily to detect more serotypes. Specificity and sensitivity in the study by Pride et al. were calculated using samples from patients of which the serotype of the pneumococcus was known to be a serotype that can be detected by the used assay, in contrast to our study. Therefore the accuracy of the tests cannot be compared correctly. In our study no samples were available for validation of the urinary assays such as the comparison set of blood samples. Although this is a drawback of the study, the good concordance of serotypes between the different assays indicates the correct assignment of serotypes.

Serotype distribution in our study was comparable to the serotype prevalence recorded by our national surveillance

system on IPD [45]. In other studies targeting CAP patients, serotype distribution was also similar, although serotype 19A is increasingly detected in studies conducted a few years after introduction of pneumococcal conjugate vaccine [46]. Furthermore, distribution of serotypes is dependent on geography. For instance, in contrast to our study, serotype 5 was detected in CAP studies in the USA and UK [46,47]. Serotype 5 is mainly found in outbreaks in Europe [48]. Of note, the serotypes that are detected in surveillance studies will depend on the methods used. For example, urinary antigen assays are often detecting only 13 or 14 serotypes [10,32]. PCRs performed on blood samples to assign a serotype detect more serotypes, but this is also limited [17,18,46].

Conclusion

In this study we assessed the use of three additional methods to identify and concurrently serotype a pneumococcus infecting patients hospitalized with CAP. Using these methods, we detected the pneumococcus in samples from 56% more patients compared to those found based on conventional methods. Also, we were able to assign a serotype to the infecting pneumococcus from samples of 25% of the patients using any of the three methods, compared to 14% of isolates obtained by blood and sputum culture suitable to determine the serotype by Quellung. This study indicates the usefulness of additional molecular methods to conventional laboratory methods for the detection of pneumococcal pneumonia. Moreover, detection of pneumococcal serotypes directly from clinical samples may improve the surveillance of the pneumococcal vaccine effectiveness.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KE, SvM, AC, CB and IvdP carried out the laboratory work of the study. SM, BV, MdJ and JM provided clinical materials. KE drafted the manuscript. LMS participated in the design of the study and planned the study. All authors have contributed intellectually during the writing process and have read and approved the final manuscript.

Acknowledgements

We thank the participating medical microbiology laboratories for collecting, analysing and sending the patients' materials to the RIVM.

Author details

¹Centre for Infectious Disease Control Netherlands, National Institute for Public Health and the Environment (RIVM), Laboratory for Infectious Diseases and Perinatal Screening, Antonie van Leeuwenhoeklaan 9, P.O.Box 1, 3720 BA Bilthoven, The Netherlands. ²Departments of Medical Microbiology & Immunology, Sint Antonius Hospital Nieuwegein, P.O box 2500, 3430 EM Nieuwegein, The Netherlands. ³Department of Internal medicine, Sint Antonius Hospital Nieuwegein, P.O box 2500, 3430 EM Nieuwegein, The Netherlands. ⁴Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands. ⁵Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands. ⁶Department of Medical Microbiology, Radboud University Medical Center,

Geert Grootplein-Zuid 10, 6525 GA Nijmegen, The Netherlands.
⁷Department of Medical Microbiology and Infectious Diseases, Canisius
 Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The
 Netherlands.

Received: 21 August 2014 Accepted: 29 January 2015

Published online: 13 February 2015

References

- File TM. Community-acquired pneumonia. *Lancet*. 2003;362(9400):1991–2001.
- Wunderink RG, Waterer GW. Clinical practice: community-acquired pneumonia. *N Engl J Med*. 2014;370(6):543–51.
- Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of *Streptococcus pneumoniae* in community-acquired pneumonia among adults in Europe: a meta-analysis. *Eur J Clin Microbiol Infect Dis*. 2013;32(3):305–16.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax*. 2012;67(1):71–9.
- Esposito S, Bosis S, Colombo R, Carlucci P, Faelli N, Fossali E, et al. Evaluation of rapid assay for detection of *Streptococcus pneumoniae* urinary antigen among infants and young children with possible invasive pneumococcal disease. *Pediatr Infect Dis J*. 2004;23(4):365–7.
- Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary antigen-detection test for *Streptococcus pneumoniae* in community-acquired pneumonia: utility and clinical impact on the reported etiology. *J Infect Chemother*. 2004;10(6):359–63.
- Lund E. Laboratory diagnosis of Pneumococcus infections. *Bull World Health Organ*. 1960;23:5–13.
- McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, Jackson GW, et al. Sensitive and specific method for rapid identification of *Streptococcus pneumoniae* using real-time fluorescence PCR. *J Clin Microbiol*. 2001;39(10):3446–51.
- van Mens SP, Meijvis SC, Endeman H, van Velzen-Blad H, Biesma DH, Grutters JC, et al. Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of *Streptococcus pneumoniae* than estimated by conventional methods alone. *Clin Vaccine Immunol*. 2011;18(5):796–801.
- Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, et al. Validation of an immunodiagnostic assay for detection of 13 *Streptococcus pneumoniae* serotype-specific polysaccharides in human urine. *Clin Vaccine Immunol*. 2012;19(8):1131–41.
- Sinclair A, Xie X, Teltcher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by *Streptococcus pneumoniae*. *J Clin Microbiol*. 2013;51(7):2303–10.
- Murdoch DR, Laing RT, Mills GD, Karalus NC, Town GI, Mirrett S, et al. Evaluation of a rapid immunochromatographic test for detection of *Streptococcus pneumoniae* antigen in urine samples from adults with community-acquired pneumonia. *J Clin Microbiol*. 2001;39(10):3495–8.
- Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. *Clin Infect Dis*. 2001;32(5):824–5.
- Smith MD, Sheppard CL, Hogan A, Harrison TG, Dance DA, Derrington P, et al. Diagnosis of *Streptococcus pneumoniae* infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. *J Clin Microbiol*. 2009;47(4):1046–9.
- Millar BC, Xu J, Moore JE. Molecular diagnostics of medically important bacterial infections. *Curr Issues Mol Biol*. 2007;9(1):21–39.
- Cremers AJ, Hagen F, Hermans PW, Meis JF, Ferwerda G. Diagnostic value of serum pneumococcal DNA load during invasive pneumococcal infections. *Eur J Clin Microbiol Infect Dis*. 2014;33(7):1119–24.
- Marchese A, Esposito S, Coppo E, Rossi GA, Tozzi A, Romano M, et al. Detection of *Streptococcus pneumoniae* and identification of pneumococcal serotypes by real-time polymerase chain reaction using blood samples from Italian children \leq 5 years of age with community-acquired pneumonia. *Microb Drug Resist*. 2011;17(3):419–24.
- Resti M, Moriondo M, Cortimiglia M, Indolfi G, Canessa C, Becciolini L, et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. *Clin Infect Dis*. 2010;51(9):1042–9.
- Azzari C, Moriondo M, Indolfi G, Massai C, Becciolini L, de Martino M, et al. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by *Streptococcus pneumoniae* in Italian children. *J Med Microbiol*. 2008;57(Pt 10):1205–12.
- Henrichsen J. Six newly recognized types of *Streptococcus pneumoniae*. *J Clin Microbiol*. 1995;33(10):2759–62.
- Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of *Streptococcus pneumoniae*. *J Clin Microbiol*. 2007;45(4):1225–33.
- Scott JA, Hall AJ, Dagan R, Dixon JM, Eykyn SJ, Fenoli A, et al. Serogroup-specific epidemiology of *Streptococcus pneumoniae*: associations with age, sex, and geography in 7,000 episodes of invasive disease. *Clin Infect Dis*. 1996;22(6):973–81.
- Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. *Microbiology*. 2010;156(Pt 2):555–60.
- Calix JJ, Nahm MH. A new pneumococcal serotype, 11E, has a variably inactivated wjE gene. *J Infect Dis*. 2010;202(1):29–38.
- Austrian R. The quellung reaction, a neglected microbiologic technique. *MtSinai J Med*. 1976;43(6):699–709.
- Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J Clin Microbiol*. 2006;44(1):124–31.
- Elberse KE, van de Pol I, Witteveen S, van der Heide HG, Schot CS, van Dijk A, et al. Population Structure of Invasive *Streptococcus pneumoniae* in the Netherlands in the Pre-Vaccination Era Assessed by MLVA and Capsular Sequence Typing. *PLoS One*. 2011;6(5):e20390.
- Elberse KE, van der Heide HG, Witteveen S, van de Pol I, Schot CS, van der Ende A, et al. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. *Vaccine*. 2012;30(52):7644–51.
- Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. *Am J Clin Pathol*. 2002;117(4):589–96.
- Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against *Streptococcus pneumoniae* polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. *Clin Vaccine Immunol*. 2010;17(4):674–82.
- Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonplex assay for the simultaneous quantitation of antibodies to nine *Streptococcus pneumoniae* serotypes. *J Immunol Methods*. 2005;296(1–2):135–47.
- Sheppard CL, Harrison TG, Smith MD, George RC. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific *streptococcus pneumoniae* antigen in urine samples. *J Med Microbiol*. 2011;60(Pt 1):49–55.
- Findlow H, Laher G, Balmer P, Broughton C, Carrol ED, Borrow R. Competitive inhibition flow analysis assay for the non-culture-based detection and serotyping of pneumococcal capsular polysaccharide. *Clin Vaccine Immunol*. 2009;16(2):222–9.
- Meijvis SC, Hardeman H, Rimmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011;377(9782):2023–30.
- Greiner O, Day PJ, Bosshard PP, Imeri F, Altwegg M, Nadal D. Quantitative detection of *Streptococcus pneumoniae* in nasopharyngeal secretions by real-time PCR. *J Clin Microbiol*. 2001;39(9):3129–34.
- Gottschalk PG, Dunn JR. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. *Anal Biochem*. 2005;343(1):54–65.
- Prentice RL. A generalization of the probit and logit methods for dose response curves. *Biometrics*. 1976;32(4):761–8.
- Abdeldaim G, Herrmann B, Molling P, Holmberg H, Blomberg J, Olcen P, et al. Usefulness of real-time PCR for *lytA*, *ply*, and *Spn9802* on plasma samples for the diagnosis of pneumococcal pneumonia. *Clin Microbiol Infect*. 2010;16(8):1135–41.
- Kellogg JA, Manzella JP, Bankert DA. Frequency of low-level bacteremia in children from birth to fifteen years of age. *J Clin Microbiol*. 2000;38(6):2181–5.
- Carvalho MG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol*. 2007;45(8):2460–6.

41. WHO CDC. Laboratory methods for the diagnosis of meningitis caused by *neisseria meningitidis*, *streptococcus pneumoniae*, and *haemophilus influenzae*: WHO manual. Geneva: World Health Organization; 2011.
42. Palmu AA, Saukkoraiji A, Snellman M, Jokinen J, Torkko P, Ziegler T, et al. Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study. *Scand J Infect Dis*. 2014;46(4):250–9.
43. Whatmore AM, Efstratiou A, Pickerill AP, Broughton K, Woodard G, Sturgeon D, et al. Genetic relationships between clinical isolates of *Streptococcus pneumoniae*, *Streptococcus oralis*, and *Streptococcus mitis*: characterization of "Atypical" pneumococci and organisms allied to *S. mitis* harboring *S. pneumoniae* virulence factor-encoding genes. *Infect Immun*. 2000;68(3):1374–82.
44. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011(1). *Emerg Infect Dis*. 2013;19(7):1074–83.
45. van Deursen AM, van Mens SP, Sanders EA, Vlamincx BJ, de Melker HE, Schouls LM, et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. *Emerg Infect Dis*. 2012;18(11):1729–37.
46. Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. *Thorax*. 2012;67(6):540–5.
47. Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, et al. Distribution of 13-valent pneumococcal conjugate vaccine *Streptococcus pneumoniae* serotypes in US adults aged ≥ 50 years with community-acquired pneumonia. *J Infect Dis*. 2013;208(11):1813–20.
48. Rolo D, Fenoll A, Fontanals D, Larrosa N, Gimenez M, Grau I, et al. Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011). *J Clin Microbiol*. 2013;51(11):3585–90.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

